Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression
- 23 January 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Neurologie
- Vol. 269 (6), 3226-3237
- https://doi.org/10.1007/s00415-021-10932-9
Abstract
Objective Our study aimed to estimate the incidence of neoplasms in clinical trials of DMTs for MS and to test the hypothesis that DMTs increase the risk of neoplasms in the duration of MS randomized controlled trials (RCTs). Methods Data were extracted from 42 RCTs of DMTs published between 1991 and 2020. The incidence rate (IR) of neoplasms was estimated by pooling the neoplasms in the active and placebo-treatment arm per patient-year. The neoplasm incidence rate ratio (IRR) of active over placebo-treatment arms was used as measure of the effect of DMTs on the risk of developing neoplasms. Results The meta-analysis included 10,638 placebo and 16,360 active-treatment arm patients. A non-significant pooled neoplasm incidence rate ratio (IRR: 1.0797; 95% CI: 0.8281 to 1.4077; P = 0.5711) with no heterogeneity (I2 = 0%) was observed in active over placebo-treatment groups from 1991 to 2020. We found a significant association between the incidence of neoplasms and the year of publication in both active and placebo arms of RCTs. Trials of sequestrating and depletive DMTs were associated with significantly higher incidence of neoplasms in both active and placebo-treated arms compared to immunomodulatory treatment trials. Conclusions Our study indicates that treatment with DMTs has not modified the risk of neoplasms in MS clinical trials from 1991 to 2020, which may reflect a low carcinogenic potential of DMTs and/or that the neoplasia latencies far exceed the typical MS trial observation periods.This publication has 32 references indexed in Scilit:
- Immuno-oncology: understanding the function and dysfunction of the immune system in cancerAnnals of Oncology, 2012
- Cancer risk in multiple sclerosis: findings from British Columbia, CanadaBrain, 2012
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publicationsBMJ, 2009
- Cancer risk among patients with multiple sclerosis and their parentsNeurology, 2009
- Second hand smoke, age of exposure and lung cancer riskLung Cancer, 2008
- Humoral immunity, inflammation and cancerCurrent Opinion in Immunology, 2007
- Cancer risk among patients with multiple sclerosis: A population‐based register studyInternational Journal of Cancer, 2005
- Cancer Incidence in Multiple Sclerosis: A 35-Year Follow-UpNeuroepidemiology, 2004
- The continuity correctionBiometrika, 1970